Elsevier

The Lancet Neurology

Volume 13, Issue 11, November 2014, Pages 1065-1067
The Lancet Neurology

Comment
CGRP as a new target in prevention and treatment of migraine

https://doi.org/10.1016/S1474-4422(14)70228-5Get rights and content

First page preview

First page preview
Click to open first page preview

References (11)

There are more references available in the full text version of this article.

Cited by (24)

  • The Itch–Scratch Cycle: A Neuroimmune Perspective

    2018, Trends in Immunology
    Citation Excerpt :

    It is tempting to postulate that behavioral responses and sensory dysfunction in other tissues such as the meninges (migraine headaches), cochlear and vestibular apparatus (tinnitus and vertigo), airway (asthma and cough), gut (irritable bowel syndrome), and bladder (interstitial cystitis) may involve a similar neuroimmune interplay as in the itch–scratch cycle. The breadth of clinical indications for itch-modulating drugs support this notion: dupilumab (anti-IL-4rα) is also being used to treat asthma [97,98] and CGRP antagonists are now indicated for migraine headaches [99] (Table 1). Similarly, SP receptor (NK-1R) antagonists are in development for chronic pruritus and PN [100], as well as Sézary syndrome, a cutaneous T cell lymphoma that is highly pruritic [101].

  • Antinociception of the spirocyclopiperazinium salt compound LXM-15 via activating α7 nAChR and M4 mAChR and inhibiting CaMKIIα/cAMP/CREB/CGRP signalling pathway in mice

    2018, Regulatory Toxicology and Pharmacology
    Citation Excerpt :

    Calcitonin gene-related peptide (CGRP), a 37-amino acid neuropeptide and a member of the calcitonin family of peptides (Malon et al., 2011), is one of the key molecular events in the nociceptive transmission and excitability of postsynaptic neurons (Oku et al., 1987). Previous studies have reported that intrathecal injection of CGRP produces a significant hyperalgesia to mechanical noxious stimuli in rats, and CGRP receptor antagonists such as telcagepant are effective in treating migraine symptoms (Diener, 2014; Ho et al., 2010; Lee et al., 2013). The present study showed that formalin injection led to an upregulation of CGRP in the DRG and spinal cord.

  • Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial

    2017, The Lancet Neurology
    Citation Excerpt :

    Small-molecule CGRP receptor antagonists, also known as gepants, have previously shown efficacy for acute treatment of migraine, although concerns with liver toxicity from telcagepant halted clinical development.26 Studies of monoclonal antibodies as preventive therapy for migraine have shown potential with respect to efficacy and safety.14,27–31 Erenumab is the only fully human monoclonal antibody in clinical development that potently binds in a competitive and reversible manner (Ki 0·02 nM) to the CGRP receptor with greater selectivity than to other human calcitonin family receptors (eg, calcitonin, amylin, and adrenomedullin).32

  • Headache and facial pain

    2016, Medicine (United Kingdom)
    Citation Excerpt :

    New options for migraine treatment, in particular calcitonin gene-related peptide antibodies, are in late-stage clinical trials.5

  • New therapeutic approaches for the prevention and treatment of migraine

    2015, The Lancet Neurology
    Citation Excerpt :

    There seems little doubt that blockade of the CGRP pathway is an effective preventive strategy of migraine, and the results of ongoing studies are eagerly awaited. However, there are also several caveats associated with this therapeutic strategy:70 none of the new monoclonal antibodies has been tested long enough to exclude adverse events on long-term use. The frequency and biological consequence of the generation of auto-antibodies against these therapeutic antibodies are still unknown.

View all citing articles on Scopus
View full text